For moderate to severe ulcerative colitis (UC)
in adult TNFi-IR patients.1

DURABLE REMISSION.1
POWERFUL HEALING.1
IN A ONCE-DAILY PILL.1

Put ulcerative colitis in check with RINVOQ

IR=intolerance or inadequate response; TNFi=tumor necrosis factor inhibitor

IR=intolerance or inadequate response;
TNFi=tumor necrosis factor inhibitor

IT'S TIME

See how RINVOQ can impact patients' lives

RAPID. DURABLE.
POWERFUL.1
  • Rapid relief of rectal bleeding and stool frequency evaluated at Week 2*

  • Durable clinical remission at Week 8 and Week 52 and steroid-free clinical remission at Week 52

  • Powerful endoscopic§ and
    histo-endoscopic|| results measured at Week 8 and Week 52

    The relationship between Histo-Endoscopic Mucosal Improvement to disease progression and long-term outcomes was not evaluated.

WELL-STUDIED
SAFETY1-5
  • Safety profile studied since 2012 with 18 phase 3 clinical trials

  • 5 approved indications across rheumatology, dermatology and gastroenterology

EXCEPTIONAL
ACCESS & SUPPORT
  • 99% preferred** commercial coverage achieved in UC6††

  • National Commercial Formulary coverage under the pharmacy benefit as of
    July 2022
  • Committed to Abbvie’s legacy of reliable access and patient support

  • RINVOQ Complete offers the same patient support you have come to expect from AbbVie

*Clinical response per partial modified Mayo Score is a composite of Mayo stool frequency and rectal bleeding subscores and is defined as a decrease in total score ≥30% and ≥1 point from baseline and a decrease in rectal bleeding subscore ≥1 or rectal bleeding subscore of 0 or 1.

Clinical remission is defined as stool frequency subscore ≤1 and not greater than baseline, rectal bleeding subscore of 0, and endoscopic subscore ≤1 without friability.

Steroid-free clinical remission is defined as clinical remission at Week 52 and corticosteroid-free for ≥90 days immediately preceding Week 52 (among patients achieving remission in induction).

§Endoscopic improvement was defined as Mayo endoscopic subscore of 0 or 1 without friability. Endoscopic results are based on a full colonoscopy or flexible sigmoidoscopy, depending on the extent of disease at study entry.

||Histo-endoscopic mucosal improvement was defined as Mayo endoscopy subscore of 0 or 1 without friability and Geboes score ≤3.1 (neutrophil infiltration in <5% of crypts, no crypt destruction, and no erosions, ulcerations, or granulation tissue). Histology results are based on a set of 2 biopsies.

Includes 6 RA phase 3 studies (SELECT- EARLY, SELECT-MONOTHERAPY, SELECT-NEXT, SELECT-COMPARE, SELECT-BEYOND, and SELECT-CHOICE); 2 PsA phase 3 studies (SELECT-PsA 1 and SELECT-PsA 2); 1 AS phase 2/3 study (SELECT-AXIS 1) and 1 AS phase 3 study (SELECT-AXIS 2); 4 AD phase 3 studies (MEASURE UP 1, MEASURE UP 2, AD UP, and HEADS UP); and 4 UC phase 3 studies (U-ACHIEVE Induction, U-ACCOMPLISH Induction, U-ACHIEVE Maintenance, and the long-term extension study).

**Formulary Definitions: Preferred means the product is placed on the plan's preferred formulary.

††Coverage requirements and benefit designs vary by payer and may change over time. Please consult with payers directly for the most current reimbursement policies.

SEE HOW RINVOQ
PUTS UC IN CHECK.
AND KEEPS IT THERE.

INDUCTION DATA1

Achieved clinical remission* at Week 8
Primary endpoint

RINVOQ induction data RINVOQ induction data RINVOQ induction data

MAINTENANCE DATA1

Achieved clinical remission* at Week 52
Primary endpoint

RINVOQ maintenance data RINVOQ maintenance data RINVOQ maintenance data

Recommended Maintenance Dosing:

A dose of 30 mg once daily may be considered for patients with refractory, severe or extensive disease. Discontinue RINVOQ if therapeutic response is not achieved with the 30 mg dose.

*Clinical remission is defined as stool frequency subscore ≤1 and not greater than baseline, rectal bleeding subscore of 0, and endoscopic subscore ≤1 without friability.

U-ACHIEVE INDUCTION & U-ACCOMPLISH Study Design Intro:1 8-week, double-blind, placebo-controlled Phase 3 clinical studies of 988 patients (473 patients for U-ACHIEVE and 515 patients for U-ACCOMPLISH) with moderately to severely active ulcerative colitis and demonstrated prior treatment failure to oral aminosalicylates, corticosteroids, immunosuppressants, and/or biologic treatment. Patients were randomized to receive either RINVOQ 45 mg or placebo once daily for 8 weeks. The primary endpoint was clinical remission per modified Mayo Score at Week 8.

U-ACHIEVE MAINTENANCE Study Design Intro:52-week, double-blind, placebo-controlled Phase 3 clinical study of 746 patients enrolled were randomized to the maintenance study. The primary efficacy analysis population was the first randomized 451 patients. Patients were randomized to receive RINVOQ 15 mg, 30 mg or placebo once daily for up to 52 weeks. The primary endpoint was clinical remission per modified Mayo Score at Week 52.

WELL-STUDIED SAFETY PROFILE
ACROSS 5 INDICATIONS1

WELL-STUDIED
SAFETY PROFILE
ACROSS 5 INDICATIONS1

RINVOQ is a JAK inhibitor
approved in
rheumatology,
dermatology, and gastroenterology1

RA, PSA, AS, AD & UC

18

phase 3 clinical trials, establishing a breadth of experience
across indications1-4,7*

>18,500

patient-years of exposure to
RINVOQ 15 or 30 mg7-11

>10,500

patients in global clinical
trials across US-approved
indications, including
pediatrics 12+ years in AD1-3,7,12

~9 YEARS

of clinical trial
experience across
indications5

*Includes 6 RA phase 3 studies (SELECT- EARLY, SELECT-MONOTHERAPY, SELECT-NEXT, SELECT-COMPARE, SELECT-BEYOND, and SELECT-CHOICE); 2 PsA phase 3 studies (SELECT-PsA 1 and SELECT-PsA 2); 1 AS phase 2/3 study (SELECT-AXIS 1) and 1 AS phase 3 study (SELECT-AXIS 2); 4 AD phase 3 studies (MEASURE UP 1, MEASURE UP 2, AD UP, and HEADS UP); and 4 UC phase 3 studies (U-ACHIEVE Induction, U-ACCOMPLISH Induction, U-ACHIEVE Maintenance, and the long-term extension study).

Includes 12,259.5 patient-years in RA trials as of 6/2021 and 2504.6 patient-years in PsA trials as of 06/2020, 577.3 patient-years in AS trials as of 08/2021 for SELECT-AXIS 2 and 08/2020 for SELECT-AXIS 1, 2787.6 patient-years in AD trials as of 11/2020, and 381.1 patient-years in one phase 3 (U-ACHIEVE Maintenance) UC trial as of 04/2021.7-11,13

RA: RINVOQ 15 mg, upadacitinib 30 mg; PsA: RINVOQ 15 mg, upadacitinib 30 mg; AS: RINVOQ 15 mg; AD: RINVOQ 15 mg and RINVOQ 30 mg; UC: RINVOQ 15 mg, 30 mg and 45 mg. RINVOQ 15 mg is the approved dose in RA, PsA, and AS; RINVOQ 15 mg and 30 mg are the approved doses in AD; RINVOQ 15 mg, 30 mg and 45 mg are the approved doses in UC.1,3,4,7,12

AD=atopic dermatitis; AS=ankylosing spondylitis; JAK=Janus kinase; PsA=psoriatic arthritis; PYs=patient-years; RA=rheumatoid arthritis; UC=ulcerative colitis

Reliable Access.
Dependable
Patient Support.

Encourage your patients to enroll in RINVOQ Complete:

1-to-1 Support:
Nurse Ambassadors* and Access Specialists
provide 1:1 support to help navigate insurance.

Affordability:
Eligible, commercially insured patients pay as little as $5 per month on their prescription and can be reimbursed for the cost of related lab tests and monitoring.

Zero dollar

Access:
No charge for eligible patients experiencing
initial insurance denial for up to 24 months.

Streamlined Enrollment Process:
Get started with a single enrollment form.

*Nurse Ambassadors are provided by AbbVie and do not provide medical advice or work under the direction of the prescribing healthcare professional (HCP). They are trained to direct patients to speak with their HCP about any treatment-related questions, including further referrals.

Eligibility criteria: Available to patients with commercial insurance coverage for RINVOQ® (upadacitinib) who meet eligibility criteria. This co-pay assistance program is not available to patients receiving prescription reimbursement under any federal, state, or government-funded insurance programs (for example, Medicare [including Part D], Medicare Advantage, Medigap, Medicaid, TRICARE, Department of Defense, or Veterans Affairs programs) or where prohibited by law. Offer subject to change or termination without notice. Restrictions, including monthly maximums, may apply. This is not health insurance. For full Terms and Conditions, visit RinvoqSavingsCard.com. To learn about AbbVie’s privacy practices and your privacy choices, visit www.abbvie.com/privacy.html

Eligibility criteria: Available to patients aged 63 or younger with commercial insurance coverage. Patients must have a valid prescription for RINVOQ® (upadacitinib) for an FDA approved indication and a denial of insurance coverage based on a prior authorization request on file along with a confirmation of appeal. Continued eligibility for the program requires the submission of an appeal of the coverage denial every 180 days. Program provides for RINVOQ® (upadacitinib) at no charge to patients for up to two years or until they receive insurance coverage approval, whichever occurs earlier, and is not contingent on purchase requirements of any kind. Program is not available to patients whose medications are reimbursed in whole or in part by Medicare, Medicaid, TRICARE, or any other federal or state program. Offer subject to change or discontinuance without notice. This is not health insurance and program does not guarantee insurance coverage. No claims for payment may be submitted to any third party for product dispensed by program. Limitations may apply.